Statistical analysis
REGRESSION
Safety data were analyzed in the all-patients-as-treated (APaT) population, which included all patients who received ≥ 1 dose of study treatment. The DLT-evaluable population included patients in the APaT population who had ≥ 75% of the planned dose per cycle for both agents and were observed for safety for 21 days as well as those who had < 75% of the planned dose but experienced a DLT.DLT rates across different dose combinations in each dose combination sequence were estimated using isotonic regression under the assumption of monotonicity between the DLT rates and dose levels for each drug; 80% CIs were provided based on the Bayesian posterior credible interval with a prior distribution of Beta (1, 1).